Symbiosis Pharmaceutical Services has purchased an injectables manufacturing facility in Scotland, UK.
The biopharma CMO has acquired the additional space to strengthen its commercial sterile injectable manufacturing services.
According to Symbiosis, the novel facility will allow the company to expedite the delivery of client’s injectable drug products to both clinical trials and commercial markets.
The site, which is centred in the Scottish city of Sterling, will double the company’s existing footprint to 43,500 sqft.
Symbiosis will also safeguard approximately 130 skilled jobs with the expansion, while making another 50 up for grabs to regional talent.
The company’s expansion was assisted by a grant from Scottish Enterprise, which awarded Symbiosis GBP £4.3m over a 3 year period to help drive the growth of both the company and Scottish pharma.
The Sterling site will include two automated sterile manufacturing production lines, with the company now offering maximum batch size of 15,000 vials to its clients.
Symbiosis’ manufacturing facility has also incorporated two sterile automated production lines, allowing it to manufacture aseptic fill/finish drug products.
Post-production, vial inspection and labelling has also been fully automated at the site.
According to Symbiosis, the facility’s regulatory inspection is due in November, meaning the site could be fully operational by the start of 2025.
Symbiosis CEO Colin MacKay commented: “By investing in this new 20,000 sq ft facility and the cutting-edge pharmaceutical manufacturing automation, Symbiosis has positioned itself to provide additional significant world-class aseptic manufacturing capacity for our existing and future clients globally and represents the next major strategic chapter in the successful and consistently fast-growing trajectory of Symbiosis.”
“This step-change in operational capacity and the addition of automation, while retaining the organisational and cultural strengths of a fantastic team here at Symbiosis, positions the company for sustained growth and the continued generation of value for clients and shareholders alike.”
